歌礼制药(01672.HK) 公布，将在西班牙马拉加举行的第32届欧洲肥胖症大会(ECO 2025)上，以口头和壁报形式报告脂肪靶向、减重不减肌的肥胖症候选药物ASC47的早期研究结果。目前美国食品药品监督管理局(FDA)已批准ASC47与司美格鲁肽联用治疗肥胖症的新药临床试验申请。(ss/a)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.